CA-NITRO-SOFTWARE
16.3.2023 01:05:39 CET | Business Wire | Press release
Nitro Software, a global leader in SaaS eSignature and PDF document solutions for businesses, announced today that Nitro Sign was again named a Leader in the GigaOm Radar Report for E-Signature Solutions.
Nitro Sign provides organizations with high-trust electronic signatures that meet or exceed global security and compliance standards, including multiple layers of protection and identity verification. The scalable solution also offers flexible integrations and APIs.
Identifying Nitro Sign as an industry Leader for the second year in a row, GigaOm acknowledged that the Nitro platform supports highly secure, end-to-end digital document processes with a seamless customer experience.
GigaOm’s 2023 Radar Report for E-Signature Solutions awarded Nitro Sign high scores for its:
- extensive compliance support, offering direct eID integration for over 30 jurisdictions
- leading data field configuration and analytics functionality
- best-in-class pricing tiers with minimal add-on fees
- automation and digitization across document workflows
- scalability and security due to its high-trust global data center strategy, extensive security provisions and tamper-proof seals at the signature (rather than envelope) level
GigaOm also noted that Nitro’s broad portfolio can support even the most complex use cases.
“The global adoption of eSignatures took off during the pandemic, and it only continues to accelerate,” said Nitro Chief Product Officer, Sam Thorpe. “Businesses of all sizes, around the world, benefit from the agility, efficiency and productivity eSignature technology enables. And while Nitro delivers a seamless customer experience, as the GigaOm Radar Report attests, there’s far more to our eSignature solutions than just enabling people to sign documents on their devices. Nitro has done the hard work behind the scenes to deliver an easy-to-use, high-trust solution that ensures our customers have the proper security, can avoid fraud and stay compliant.”
GigaOm’s Radar Report notes: “To be a significant player in this space, an e-signature solution must not only support the core e-signature process (preparation, distribution, execution) but also offer extensive compliance support, scalability for high-volume use cases, and flexibility across a range of countries, languages and interfaces. Functionality that simply allows a user to draw a signature on a document is not sufficient to be considered in this report.”
The report adds that “businesses are looking for end-to-end process capabilities rather than standalone solutions. In other words, e-signatures are viewed as a core component of broader document management suites, potentially not something an enterprise would purchase on its own. SMBs will shift more gradually to this strategy but will follow a similar path….”
In its 2023 Radar Report, GigaOm delivers comprehensive evaluations of 14 leading eSignature vendors, an analysis of each of their offerings and provides expert guidance on how to choose the right eSignature vendor for both small and medium business and enterprise requirements.
To read more about Nitro’s position and learn more about what’s happening with eSignatures, click here for a complimentary copy of the GigaOm Radar Report for E-Signature Solutions.
About Nitro Software
Nitro (ASX: NTO) is a global SaaS leader in PDF document management and eSigning. Nitro’s Productivity Platform includes powerful PDF tools, digital workflow automation, highly secure eSigning and identity capabilities. Its industry-leading analytics solution measures and quantifies ROI, usage and sustainability impact. With a best-in-class customer success team, Nitro supports more than 67% of the Fortune 500, 3 million licensed users and 13,000+ business customers across 157 countries. For more information: visit https://gonitro.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005670/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom